Otezla (apremilast) is an oral biologic medication that was FDA approved for the treatment of moderate to server plaque psoriasis in September 2014. Otezla was previously approved for the treatment of active psoriatic arthritis in March 2014.
Otezla works by reducing inflammation. It inhibits an enzyme known as phosphodiesterase 4 (PDE4). PDE4 controls much of the inflammation caused by the immune system. By reducing skin inflammation, the medication reduces the symptoms (redness, tenderness, scaliness) of psoriasis.
Otezla is taken by mouth within an initial 5-day “start period”. The dosage is gradually increased until the recommended dose of 30 mg twice each day is reached. Otezla is taken continuously to maintain control of psoriasis symptoms.
In clinical trials of Otezla, about 31% of of those who took Otezla experienced a 75% improvement in the severity of their psoriasis after four months.
Learn more from the National Psoriasis Foundation – Otezla (apremilast)